Cytochroma Announces Appointment of Peter Moldt to Board of Directors
"We are very pleased to welcome
Dr. Moldt has significant experience in corporate strategy, company operations, and drug development. He was most recently CEO of Curalogic A/S, a company he cofounded in 2004 and subsequently took public. Before Curalogic A/S, he was Chief Operating Officer of 7TM Pharma A/S, a company which he cofounded in 2000. Prior to 2000, Dr. Moldt spent 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development. Dr. Moldt holds a PhD in medicinal chemistry from the Royal Danish School of Pharmacy, and has been a post-doc with
Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma has three product candidates in clinical development for CKD patients: CTA018 Injection and CTAP201 Injection are being developed for the treatment of SHPT in stage 5 CKD, while CTAP101 Capsules are being developed for the treatment of vitamin D insufficiency and associated SHPT in stage 3 and 4 CKD. CTA018 Injection is being developed in partnership with Mitsubishi Tanabe Pharma Corporation for the U.S. and Asian markets, and Cytochroma retains co-promotion rights for this product in the U.S. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in CKD patients.
For more information about Cytochroma, please visit www.cytochroma.com.